retatrutide approval Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. @adamyamaguchi ⚠️ BEWARE OF RETATRUTIDE SOLD

Semaglutide is unusual: it's on-patent, commercially available, and still legally compoundable due to shortage status

The observed protective association between GLP1-RAs and PI in the context of glycated hemoglobin lowering may be due to the efficacy of GLP-1RAs in lowering blood glucose, which could mitigate hyperglycemic mesenteric microvascular damage and therefore improve blood flow to the ileum [31], reducing the risk for PI

Retatrutide vs Tirzepatide: Triple vs Dual Receptor Research Explained Retatrutide and Tirzepatide are two of the most searched compounds in modern incretin-based research

Detta lkemedel r en GLP-1-receptoragonist, vilket innebr att det aktiverar GLP-1-receptorn

But that doesnt mean its the best fit for everybody

Retatrutide posted 24% body weight loss in Phase 2 by targeting three receptors instead of one